Mineralys' blood pressure drug meets goal in trials, shares soar

March 10 (Reuters) - Mineralys Therapeutics MLYS.O said on Monday its experimental drug met the main goal of lowering blood pressure in patients with uncontrolled or resistant hypertension in late- and mid- stage trials, sending its shares up about 43% before the bell.

In the late-stage study, the treatment called lorundrostat showed a placebo-adjusted reduction in systolic blood pressure by 9.1 mmHg (millimeters of mercury) at week six. The benefit was sustained through week 12, with a further reduction to 11.7 mmHg.

The drug also reduced systolic blood pressure by 7.9 mmHg in a mid-stage trial when compared to a placebo, the company said.

Lorundrostat inhibits the production of aldosterone, a hormone that can contribute to high blood pressure.